244 related articles for article (PubMed ID: 20942634)
21. Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.
Fornaro L; Vivaldi C; Caparello C; Sacco R; Rotella V; Musettini G; Luchi S; Baldini EE; Falcone A; Masi G
Future Oncol; 2014 Feb; 10(2):285-304. PubMed ID: 24490614
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Montella L; Palmieri G; Addeo R; Del Prete S
World J Gastroenterol; 2016 Jul; 22(27):6114-26. PubMed ID: 27468204
[TBL] [Abstract][Full Text] [Related]
24. Molecular targeted therapy in hepatocellular carcinoma: present achievements and future challenges.
Giacomin A; Sergio A; Vanin V; Gazzola A; Cazzagon N; Farinati F
Dig Dis; 2012; 30(3):284-8. PubMed ID: 22722553
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
Chen KF; Tai WT; Liu TH; Huang HP; Lin YC; Shiau CW; Li PK; Chen PJ; Cheng AL
Clin Cancer Res; 2010 Nov; 16(21):5189-99. PubMed ID: 20884624
[TBL] [Abstract][Full Text] [Related]
26. Antiangiogenic strategies in hepatocellular carcinoma: current status.
Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
[TBL] [Abstract][Full Text] [Related]
27. Molecularly targeted therapy in hepatocellular carcinoma.
Huynh H
Biochem Pharmacol; 2010 Sep; 80(5):550-60. PubMed ID: 20371362
[TBL] [Abstract][Full Text] [Related]
28. Systemic therapies in hepatocellular carcinoma.
Wörns MA; Weinmann A; Schuchmann M; Galle PR
Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
30. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
Lee JM; Han KH
Oncology; 2010 Jul; 78 Suppl 1():167-71. PubMed ID: 20616600
[TBL] [Abstract][Full Text] [Related]
31. [Molecular structure and abnormal expression of angiopoietin-2 and antiangiogenic targeting therapy of hepatocelluar carcinoma].
GU WJ; YAO DF
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):398-400. PubMed ID: 19497214
[No Abstract] [Full Text] [Related]
32. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Zhu AX
Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
[TBL] [Abstract][Full Text] [Related]
33. Anti-angiogenic therapy for HCC.
Dufour JF
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):81-6. PubMed ID: 22419006
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
35. The role of tyrosine kinase inhibitors in hepatocellular carcinoma.
Kim S; Abou-Alfa GK
Clin Adv Hematol Oncol; 2014 Jan; 12(1):36-41. PubMed ID: 25000314
[TBL] [Abstract][Full Text] [Related]
36. Future perspectives in hepatocellular carcinoma.
Wörns MA; Galle PR
Dig Liver Dis; 2010 Jul; 42 Suppl 3():S302-9. PubMed ID: 20547319
[TBL] [Abstract][Full Text] [Related]
37. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
[TBL] [Abstract][Full Text] [Related]
38. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
39. Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.
Berz D; Wanebo H
J Surg Oncol; 2011 May; 103(6):574-86. PubMed ID: 21480252
[TBL] [Abstract][Full Text] [Related]
40. New agents in hepatocellular carcinoma.
Abou-Alfa GK
Clin Adv Hematol Oncol; 2008 Jun; 6(6):423-4. PubMed ID: 18567988
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
